Shares of China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC - Get Free Report) traded down 5.7% during mid-day trading on Monday . The company traded as low as $1.46 and last traded at $1.48. 36,926 shares changed hands during mid-day trading, a decline of 6% from the average session volume of 39,235 shares. The stock had previously closed at $1.57.
Wall Street Analyst Weigh In
Separately, Wall Street Zen upgraded shares of China SXT Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, August 2nd.
Check Out Our Latest Research Report on SXTC
China SXT Pharmaceuticals Stock Performance
The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.40 and a current ratio of 3.54. The firm's 50-day moving average is $1.67 and its 200-day moving average is $2.23.
China SXT Pharmaceuticals Company Profile
(
Get Free Report)
China SXT Pharmaceuticals, Inc, a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider China SXT Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and China SXT Pharmaceuticals wasn't on the list.
While China SXT Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access